sur Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics to Attend Jefferies Global Healthcare Conference 2025
Protagonist Therapeutics, Inc., a biopharmaceutical company from Newark, CA, announced its participation in the Jefferies Global Healthcare Conference in New York, scheduled for June 3-5, 2025. CEO Dinesh V. Patel will present a company overview on June 4 at 1:25 P.M. ET. The company will also hold one-on-one meetings.
A webcast of the presentation will be available on Protagonist's Investor Relations web page for one year post-event. Those interested in meetings can contact their Jefferies representative.
Protagonist Therapeutics focuses on drug discovery and development. Their key projects include icotrokinra, developed with Johnson & Johnson, and rusfertide, in collaboration with Takeda Pharmaceuticals. Both are in Phase 3 clinical trials aiming for FDA submissions in 2025.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Protagonist Therapeutics, Inc.